

Reference List

Title:

State of the Art Therapeutic Treatments for IBS Patients: Understanding the Role of the Gastroenterologist, Dietitian, and GI Psychologist, by Dr. William Chey, MD, Kate Scarlata, MPH, RDN, and Megan Riehl, PsyD

References:

1. Ali A, Weiss TR, McKee D, et al. Efficacy of individualised diets in patients with irritable bowel syndrome: a randomised controlled trial. *BMJ Open Gastroenterol*. 2017;4:e000164.
2. Böhn L, Störsrud S, Törnblom H, Bengtsson U, Simrén M. Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. *Am J Gastroenterol*. 2013;108(5):634-641.
3. Chey WD. Food: the main course to wellness and illness in patients with irritable bowel syndrome. *Am J Gastroenterol*. 2016;111(3):366-371.
4. Chey WD. Elimination diets for irritable bowel syndrome: approaching the end of the beginning. *Am J Gastroenterol*. 2019;114(2):201-203.
5. Chung BY, Park SY, Byun YS, et al. Effect of different cooking methods on histamine levels in selected foods. *Ann Dermatol*. 2017;29(6):706-714.
6. Dionne J, Ford AC, Yuan Y, et al. A systematic review and meta-analysis evaluating the efficacy of a gluten-free diet and a low FODMAPs diet in treating symptoms of irritable bowel syndrome. *Am J Gastroenterol*. 2018;113(9):1290-1300.
7. Eswaran SL, Chey WD, Han-Markey T, Ball S, Jackson K. A randomized controlled trial comparing the low FODMAP diet vs. modified NICE guidelines in US adults with IBS-D. *Am J Gastroenterol*. 2016;111(12):1824-1832.
8. Eswaran S, Dolan RD, Ball SC, Jackson K, Chey W. The impact of a 4-week low-FODMAP and mNICE Diet on nutrient intake in a sample of US adults with irritable bowel syndrome with diarrhea. *J Acad Nutr Diet*. 2020;120(4):641-649.
9. Eswaran SL, Zheng T, D'Amato M, Chey WD. 347 — is sucrose the sixth FODMAP in a subset of patients with irritable bowel syndrome with diarrhea and sucrase isomaltase deficiency? *Gastroenterology*. 2019;156(6 Suppl 1):S69-S70.
10. Eswaran S, Tack J, Chey WD. Food: the forgotten factor in the irritable bowel syndrome. *Gastroenterol Clin North Am*. 2011;40(1):141-162.
11. Enko D, Meinitzer A, Mangge H, et al. Concomitant prevalence of low serum diamine oxidase activity and carbohydrate malabsorption. *Can J Gastroenterol Hepatol*. 2016;2016:4893501.
12. Ford AC, Quigley EM, Lacy BE, et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. *Am J Gastroenterol*. 2014;109(9):1350-1365.
13. Fritscher-Ravens A, Pflaum T, Mössinger M, et al. Many patients with irritable bowel syndrome have atypical food allergies not associated with immunoglobulin E. *Gastroenterology*. 2019;157(1):109-118.e5.
14. Garcia-Etxebarria K, Zheng T, Bonfiglio F, et al. Increased prevalence of rare sucrase-isomaltase pathogenic variants in irritable bowel syndrome patients. *Clin Gastroenterol Hepatol*. 2018;16(10):1673-1676.
15. Gracie DJ, Guthrie EA, Hamlin PJ, Ford AC. Bi-directionality of brain-gut interactions in patients with inflammatory bowel disease. *Gastroenterology*. 2018;154(6):1635-1646.

16. Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Gibson PR, Muir JG. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. *Gut*. 2015;64(1):93-100.
17. Halmos EP, Gibson PR. Controversies and reality of the FODMAP diet for patients with irritable bowel syndrome. *J Gastroenterol Hepatol*. 2019;34(7):1134-1142.
18. Harer K, Baker J, Reister N, et al. Avoidant/restrictive food intake disorder in the adult gastroenterology population: an under-recognized diagnosis? *Am J Gastroenterol*. 2018;113(Suppl):S247-S248.
19. He M, Sun J, Jiang ZQ, Yang YX. Effects of cow's milk beta-casein variants on symptoms of milk intolerance in Chinese adults: a multicentre, randomised controlled study. *Nutr J*. 2017;16(1):72.
20. Henström M, Diekmann L, Bonfiglio F, et al. Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome. *Gut*. 2018;67(2):263-270.
21. Hill P, Muir J, Gibson P. Controversies and recent developments of the low-FODMAP diet. *Gastroenterol Hepatol (N Y)*. 2017;13(1):36-45.
22. Husein DM, Naim HY. Impaired cell surface expression and digestive function of sucrase-isomaltase gene variants are associated with reduced efficacy of low FODMAPs diet in patients with IBS-D [published online July 22, 2019]. *Gut*. doi: 10.1136/gutjnl-2019-319411.
23. Junker Y, Zeissig S, Kim SJ, et al. Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4. *J Exp Med*. 2012;209(13):2395-2408.
24. Keefer L, Palsson OS, Pandolfino JE. Best practice update: incorporating psychogastroenterology into management of digestive disorders. *Gastroenterology*. 2018;154(5):1249-1257.
25. Kim HS, Patel KG, Orosz E, et al. Time trends in the prevalence of celiac disease and gluten-free diet in the US population: results from the National Health and Nutrition Examination Surveys 2009-2014. *JAMA Intern Med*. 2016;176(11):1716-1717.
26. Kinsinger SW. Cognitive-behavioral therapy for patients with irritable bowel syndrome: current insights. *Psychol Res Behav Manag*. 2017;10:231-237.
27. Labus JS, Mayer EA, Chang L, Bolus R, Naliboff BD. The central role of gastrointestinal-specific anxiety in irritable bowel syndrome: further validation of the visceral sensitivity index. *Psychosom Med*. 2007;69(1):89-98.
28. Laird KT, Tanner-Smith EE, Russell AC, Hollon SD, Walker LS. Short-term and long-term efficacy of psychological therapies for irritable bowel syndrome: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. 2016;14(7):937-947.
29. Lee C, Doo E, Choi JM, et al. The increased level of depression and anxiety in irritable bowel syndrome patients compared with healthy controls: systematic review and meta-analysis. *J Neurogastroenterol Motil*. 2017;23(3):349-362.
30. Lomer MC. Review article: the aetiology, diagnosis, mechanisms and clinical evidence for food intolerance. *Aliment Pharmacol Ther*. 2015;41(3):261-276.
31. Maintz L, Novak N. Histamine and histamine intolerance. *Am J Clin Nutr*. 2007;85(5):1185-1196.
32. Mearin F, Lacy BE, Chang L, et al. Bowel disorders [published February 18, 2016]. *Gastroenterology*. doi: 10.1053/j.gastro.2016.02.031.
33. Miller V, Carruthers HR, Morris J, Hasan SS, Archbold S, Whorwell PJ. Hypnotherapy for irritable bowel syndrome: an audit of one thousand adult patients. *Aliment Pharmacol Ther*. 2015;41(9):844-855.
34. Molina-Infante J, Carroccio A. Suspected nonceliac gluten sensitivity confirmed in few patients after gluten challenge in double-blind, placebo-controlled trials. *Clin Gastroenterol Hepatol*. 2017;15(3):339-348.
35. Morgan JF, Reid F, Lacey JH. The SCOFF questionnaire: assessment of a new screening tool for eating disorders. *BMJ*. 1999;319(7223):1467-1468.

36. Mukhtar K, Nawaz H, Abid S. Functional gastrointestinal disorders and gut-brain axis: what does the future hold? *World J Gastroenterol*. 2019;25(5):552-566.
37. Ortolani C, Pastorello EA. Food allergies and food intolerances. *Best Pract Res Clin Gastroenterol*. 2005;20(3):467-483.
38. Palsson O, Turner MJ, Johnson DA, Burnett CK, Whitehead WE. Hypnosis treatment for severe irritable bowel syndrome: investigation of mechanism and effects on symptoms. *Dig Dis Sci*. 2002;47(11):2605-2614.
39. Palsson OS, van Tilburg M. Hypnosis and guided imagery treatment for gastrointestinal disorders: experience with scripted protocols developed at the University of North Carolina. *Am J Clin Hypn*. 2015;58(1):5-21.
40. Peters S, Yao CK, Philpott H, Yelland GW, Muir JG, Gibson PR. Randomised clinical trial: the efficacy of gut-directed hypnotherapy is similar to that of the low FODMAP diet for the treatment of irritable bowel syndrome. *Aliment Pharmacol Ther*. 2016;44(5):447-459.
41. Potter MDE, Walker MM, Jones MP, Koloski NA, Keely S, Talley NJ. Wheat intolerance and chronic gastrointestinal symptoms in an Australian population-based study: association between wheat sensitivity, celiac disease and functional gastrointestinal disorders. *Am J Gastroenterol*. 2018;113(7):1036-1044.
42. Riehl ME, Kinnucan JA, Chey WD, Stidham RW. Nuances of the psychogastroenterology patient: a predictive model for gastrointestinal quality of life improvement. *Neurogastroenterol Motil*. 2019;31(9):e13663.
43. Rossi M, Aggio R, Staudacher HM, et al. Volatile organic compounds in feces associate with response to dietary intervention in patients with irritable bowel syndrome. *Clin Gastroenterol Hepatol*. 2018;16(3):385-391.e1.
44. Schuppan D, Pickert G, Ashfaq-Khan M, Zevallos V. Non-celiac wheat sensitivity: differential diagnosis, triggers and implications. *Best Pract Res Clin Gastroenterol*. 2015;29(3):469-476.
45. Shepherd SJ, Parker FC, Muir JG, Gibson PR. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. *Clin Gastroenterol Hepatol*. 2008;6(7):765-771.
46. Skodje GI, Sarna VK, Minelle IH, et al. Fructan, rather than gluten, induces symptoms in patients with self-reported non-celiac gluten sensitivity. *Gastroenterology*. 2018;154(3):529-539.
47. Satherley R, Howard R, Higgs S. Disordered eating practices in gastrointestinal disorders. *Appetite*. 2015;84:240-250.
48. Spencer M, Chey WD, Eswaran S. Dietary renaissance in IBS: has food replaced medications as a primary treatment strategy? *Curr Treat Options Gastroenterol*. 2014;12(4):424-440.
49. Vasant DH, Whorwell PJ. Gut-focused hypnotherapy for functional gastrointestinal disorders: evidence-base, practical aspects, and the Manchester Protocol. *Neurogastroenterol Motil*. 2019;31(8):e13573.
50. Valeur J, Småstuen MC, Knudsen T, Lied GA, Røseth AG. Exploring gut microbiota composition as an indicator of clinical response to dietary FODMAP restriction in patients with irritable bowel syndrome. *Dig Dis Sci*. 2018;63(2):429-436.
51. Van Oudenhove L, Crowell MD, Drossman DA, et al. Biopsychosocial aspects of functional gastrointestinal disorders [published February 18, 2016]. *Gastroenterology*. doi: 10.1053/j.gastro.2016.02.027.
52. Vazquez-Roque MI, Camilleri M, Smyrk T, et al. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. *Gastroenterology*. 2013;144(5):903-911.e3.

53. Zamani M, Alizadeh-Tabari S, Zamani V. Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome. *Aliment Pharmacol Ther.* 2019;50(2):132-143.
54. Zevallos VF, Raker V, Tenzer S, et al. Nutritional wheat amylase-trypsin inhibitors promote intestinal inflammation via activation of myeloid cells. *Gastroenterology.* 2017;152(5):1100-1113.
55. Zheng T, Eswaran S, Photenhauer AL, Merchant JL, Chey WD, D'Amato M. Reduced efficacy of low FODMAPs diet in patients with IBS-D carrying sucrase-isomaltase (SI) hypomorphic variants. *Gut.* 2020;69(2):397-398.
56. Zickgraf HF, Ellis JM. Initial validation of the nine item avoidant/restrictive food intake disorder screen (NIAS): a measure of three restrictive eating patterns. *Appetite.* 2018;123:32-42.